The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide health crisis. To support COVID-19 research, Kactus has developed a series of SARS-CoV-2 and SARS antigens including domains of spike (S) proteins, host cell receptor ACE2.
We are also offering personalized service that customers demand.
Low-endotoxin(<1EU per μg by the LAL method) and high-purity (>95%);
High degree of batch-to-batch consistency;
Featured protein expression screening system for high-yield product (up to several grams);
Offering biotinylated proteins, with highest bioactivity and sensitivity.
Fig. 1 SDS-PAGE of SARS-CoV-2 Spike S1 and bioactivity assay by ELISA.
Fig. 2 Human ACE2 captured on Protein A chip, can bind SARS-COV-2 Spike RBD, His Tag with an affinity constant of 13.8nM as determined in a SPR assay(Biacore T200).
Fig. 3 Human ACE2 captured on Protein A chip, can bind SARS-COV-2 Spike RBD(N501Y), His Tag with an affinity constant of 1.74nM as determined in a SPR assay(Biacore T200).